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Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations
by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We
investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for
476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios
(HRs) and 95% conﬁdence intervals (CIs) were estimated using Cox models. During a mean follow-up of 14 years,
220 esophageal adenocarcinomas (EA), 195 esophageal squamous cell carcinomas, 243 gastric cardia (GC) and 373 gastric
noncardia (GNC) cancers were diagnosed. Body mass index (BMI) was associated with EA in men (BMI ≥30 vs. 18.5–25 kg/m2:
HR = 1.94, 95% CI: 1.25–3.03) and women (HR = 2.66, 95% CI: 1.15–6.19); however, adjustment for waist-to-hip ratio (WHR)
attenuated these associations. After mutual adjustment for BMI and HC, respectively, WHR and waist circumference (WC) were
associated with EA in men (HR = 3.47, 95% CI: 1.99–6.06 for WHR >0.96 vs. <0.91; HR = 2.67, 95% CI: 1.52–4.72 for WC >98
vs. <90 cm) and women (HR = 4.40, 95% CI: 1.35–14.33 for WHR >0.82 vs. <0.76; HR = 5.67, 95% CI: 1.76–18.26 for WC >84 vs.
<74 cm). WHR was also positively associated with GC in women, and WC was positively associated with GC in men. Inverse
associations were observed between parity and EA (HR = 0.38, 95% CI: 0.14–0.99; >2 vs. 0) and age at ﬁrst pregnancy and
GNC (HR = 0.54, 95% CI: 0.32–0.91; >26 vs. <22 years); whereas bilateral ovariectomy was positively associated with GNC
(HR = 1.87, 95% CI: 1.04–3.36). These ﬁndings support a role for hormonal pathways in upper gastrointestinal cancers.
What’s new?
Obesity can change the body’s hormone balance, and encourage the onset of cancer. Here, the authors investigated the
relationship between obesity, hormones, and esophageal and gastric cancers. Using data from the EPIC cohort, they obtained
information about anthropometric and reproductive factors for 476,160 participants. Excess fat around the waist, they found,
was associated with esophageal adenocarcinoma and gastric cardia cancer, in women and men. In women, bearing children, as
well as younger age at ﬁrst pregnancy, had an inverse association with certain cancers. Ovariectomy was positively associated
with gastric non-cardia cancer, suggesting involvement of hormone pathways in these malignancies.
2 Anthropometric and hormonal factors and upper gastrointestinal cancer
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Introduction
Esophageal cancer is the seventh most common and gastric can-
cer the ﬁfth most common cancer worldwide, with an estimated
572,000 and 1,000,000 cases in 2018, respectively.1 These can-
cers are more common in men than in women and are becom-
ing more prevalent in many regions of the world.1 Esophageal
cancer can be categorized histologically as esophageal adenocar-
cinoma (EA) and esophageal squamous cell carcinoma (ESCC)
and these subtypes have distinct etiologies. Gastric cancers are
predominantly adenocarcinomas but their etiology appears to
differ depending on their location in the gastric cardia (GC) or
gastric noncardia (GNC). Smoking and alcohol are well-known
risk factors for ESCC, whereas gastroesophageal reﬂux disease
(GERD), smoking and obesity are established risk factors for
EA.2 Smoking and obesity are also thought to be risk factors for
GC, while Helicobacter pylori infection and smoking are risk
factors for GNC.3
The role of obesity in upper gastrointestinal cancers has
been previously investigated in a number of epidemiological
studies.4–10 Two studies conducted within the European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
cohort, reported a positive association between body mass
index (BMI) and EA.4,5 Two other analyses found a positive
association between BMI and risk of EA and GC.11,12 In addi-
tion, the recent report from the World Cancer Research Fun-
d/American Institute for Cancer Research (WCRF/AICR)
concluded that there is “convincing” evidence that BMI
increases the risk of EA.13 Conversely, an inverse association
between BMI and ESCC risk has been reported in several epi-
demiological studies.2,4,7,14 The WCRF/AICR report also con-
cluded that there is “probable” evidence that BMI increases
the risk of GC.13 However, few epidemiological studies have
examined the association between abdominal obesity and risk
of esophageal and gastric cancer by subtype or subsite and the
published ﬁndings are inconsistent.4,5,8,15
There are several plausible biological mechanisms underly-
ing the association between obesity and upper gastrointestinal
cancers. Obesity promotes GERD and its transition to
Barrett’s esophagus, which increases the risk of EA and
GC.12,16 Obesity is also associated with a range of metabolic
and endocrinologic abnormalities. In particular, obesity can
lead to insulin resistance, where circulating levels of insulin
and bioavailable insulin-like growth factor (IGF) are elevated,
leading to stimulation of cell proliferation and downregulation
of apoptosis.17 Obese individuals also have abnormal circulat-
ing levels of adipokines (e.g., higher levels of leptin and lower
levels of adiponectin), proinﬂammatory cytokines (e.g., tumor
necrosis factor-α and interleukin-6) and endogenous sex ste-
roids, which are synthesized in peripheral adipose tissue and
may contribute to cancer development.17,18
In addition to the link through obesity, sex hormones
could also explain the predominance of both esophageal and
gastric cancers in men compared to women. It has been
suggested that female sex hormones, particularly estrogens,
may protect against the development of esophageal and gastric
cancer.19,20 Some epidemiological studies have investigated the
role of hormonal and reproductive factors in the development
of esophageal and gastric cancer risk21–24; however, prospec-
tive studies examining these relationships by subtype of
esophageal cancer and subsite of gastric cancer are limited,
with conﬂicting results.25–29 The association between repro-
ductive factors and gastric cancer was investigated in a previ-
ous analysis of the EPIC cohort, which included participants
with follow-up through 2004; this analysis showed a positive
association between ovariectomy and gastric cancer risk.28 In
the present study, not only did we have much longer follow-
up of the EPIC cohort data, and therefore more cases, but also
we studied the role of reproductive factors in both esophageal
and gastric cancer by subtype and subsite.
The aim of the current study was to investigate both
anthropometric and reproductive factors in relation to esoph-
ageal and gastric cancer by subtype and subsite, respectively,
in a large cohort study with long-term follow-up.
Materials and Methods
Study population
The EPIC study is an ongoing multicenter prospective cohort
study aimed at investigating the association between diet, life-
style, genetic and environmental factors and the development
of cancer and other chronic diseases. The methodological
details and rationale of the EPIC study have been described
previously.30,31 In brief, the cohort comprises of 521,448 men
and women, aged 25–70 years, recruited between 1992 and
2000 from 23 centers located in 10 European countries includ-
ing Denmark, France, Germany, Greece, Italy, Norway, Spain,
Sweden, the Netherlands and the United Kingdom. Partici-
pants were mostly recruited from the general population with
some exceptions: French participants were recruited via health
insurance databases; some participants of the Italian and Span-
ish cohorts were recruited through local blood donor registries;
participants of the Utrecht (the Netherlands) and Florence
(Italy) cohorts were recruited via breast cancer screening pro-
grams; the Oxford (United Kingdom) cohort included a large
proportion of vegetarians. All participants signed an informed
consent form and the study was approved by the ethical
review committees of the International Agency for Research on
Cancer (IARC) and EPIC centers.
For our study, we excluded participants with prevalent
cancer at recruitment (n = 29,332), participants who were lost
during follow-up (n = 124), participants for whom no dietary
or lifestyle information was available (n = 6,259) and partici-
pants who were in the top or bottom 1% of the ratio of energy
intake to estimated energy requirement (n = 9,573). After the
exclusions, the ﬁnal sample available for the analysis included
476,160 participants.
Diet and lifestyle questionnaires
Usual diet was assessed at recruitment using validated
country-speciﬁc dietary questionnaires reﬂecting intake in the
past 12 months. A separate questionnaire on lifestyle factors
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was used to collect information on smoking and alcohol con-
sumption, education, occupation, reproductive history, family
history and physical activity.
Assessment of anthropometric and reproductive data
Anthropometric measurements including height, weight, waist
circumference (WC) and hip circumference (HC) were taken
at recruitment by trained health professionals in most EPIC
centers, except for most of the Oxford cohort, the Norwegian
cohort and approximately two-thirds of the French cohort, in
which height and weight were self-reported. BMI was com-
puted as weight in kilograms divided by height in meters
squared, waist-to-hip ratio (WHR) was computed as WC
(cm) divided by HC (cm) and waist-to-height ratio (WHtR)
was computed as WC (cm) divided by height (cm).
Information on reproductive history was collected at recruit-
ment. The following reproductive characteristics were assessed:
age at menarche, duration of menstrual cycle, ever been preg-
nant, age at ﬁrst pregnancy, number of full-term pregnancies
(parity), number of live-born children, breastfeeding, meno-
pausal status, age at menopause, menopausal hormone use, oral
contraceptive (OC) pill use and ovariectomy. More details on
questionnaires can be found elsewhere.30,31
Follow-up and identiﬁcation of cancer cases
Participants were followed-up from study entry until cancer
diagnosis, death or end of follow-up, which is currently up to
2015, whichever came ﬁrst. Population-based cancer registries,
as well as postal follow-up questionnaires, are used in most of
the countries to identify incident cancer cases. In France, Ger-
many, Greece and Naples (Italy) cancer cases are additionally
identiﬁed through active follow-up. Data on mortality and
movement of participants are obtained through periodic link-
age to regional and national mortality registries. First primary
incident esophageal and gastric cancers were coded according
to the 10th revision of the International Classiﬁcation of Dis-
eases (ICD-10). Esophageal cancer included topography ICD-
O codes C15.0–C15.9; EA was categorized as (ICD-O mor-
phological codes: 8140, 8141, 8190–8231, 8260–8263, 8310,
8430, 8480–8490, 8560, 8570–8572) and ESCC was catego-
rized as (ICD-O morphological codes: 8050–8076). Gastric
adenocarcinomas included topography ICD-O codes: C16; GC
was classiﬁed as ICD-O code C16.0 and GNC included
C16.1–16.6.
Statistical analysis
Cox proportional hazard models were used to calculate hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) for the associa-
tion between anthropometric and reproductive factors and risk
of esophageal and gastric cancer by subtype and subsite, respec-
tively. Age was used as the primary time metric, and entry time
was deﬁned as age at enrolment and exit time as age at diagno-
sis, death or end of follow-up, whichever occurred ﬁrst. Models
were stratiﬁed by age at recruitment and study center.
Anthropometric variables. To account for different body fat
distributions of men and women, we used sex-speciﬁc tertiles for
anthropometric variables (height, weight, WC, HC, WHR and
WHtR). BMI was classiﬁed according to World Health Organi-
zation (WHO) categories: underweight (BMI < 18.5 kg/m2), nor-
mal weight (18.5 ≤ BMI < 25 kg/m2), overweight (25 ≤ BMI
< 30 kg/m2) and obese (≥30 kg/m2). Mean and standard devia-
tions or frequencies were calculated for baseline characteristics
of study participants stratiﬁed by BMI categories. All models
were adjusted for smoking status (never smoker; former smoker
who stopped ≤10, 11–20 or 20+ years ago; current smoker of
1–15, 16–25 or 26+ cigarettes/day; current or occasional
pipe/cigar; smoking unknown/missing), and education level
(none, primary school, technical/professional, secondary school
or university), while models for ESCC were additionally adjusted
for alcohol intake (g/day). We also examined models in which
BMI and WHR were mutually adjusted, to estimate whether
abdominal obesity was associated with upper gastrointestinal
cancers independently of the association with general obesity. In
addition, separate models were used in which WC and HC were
mutually adjusted for each other. Interactions between anthro-
pometric variables with sex and smoking status were explored
by including an interaction term along with the main effect term
in the adjusted model. The likelihood ratio test was used to com-
pare models with and without interaction terms.
Reproductive variables. Reproductive variables were classi-
ﬁed into categories as follows: age at menarche (<12, 12–14,
>14 years), duration of menstrual cycling (<30, 30–35,
>35 years), ever been pregnant (yes/no), age at ﬁrst pregnancy
(<22, 22–26, >26 years), parity (0, 1–2, >2 pregnancies), num-
ber of live-born children (1, 2–3, >3), breastfeeding (yes/no),
duration of breastfeeding (<4, 4–10, >10 months), menopausal
status (pre/perimenopausal, postmenopausal), age at meno-
pause (<48, 48–51, >51 years), menopausal hormone use
(yes/no), duration of menopausal hormone use (<2, ≥2 years),
OC pill use (yes/no), duration of OC pill use (<5, ≥5 years)
and ovariectomy (no, unilateral, bilateral). We computed
mean and standard deviations or frequencies for baseline
characteristics in women stratiﬁed by OC and menopausal
hormone use. Models for EA, GC and GNC were adjusted for
smoking status, BMI and educational level, while models for
ESCC were additionally adjusted for alcohol intake (g/day).
Tests for linear trend across categories of anthropometric
and reproductive variables were performed by assigning the
median value to each category as a continuous term in the
Cox regression models.
To examine possible reverse causation, we performed sensi-
tivity analyses by excluding esophageal and gastric cancer cases
diagnosed in the ﬁrst 2 years of follow up. Additional sensitivity
analyses included restricting the analyses to participants in
whom height and weight were measured rather than self-
reported. To examine whether the excluded participants dif-
fered from those included, we compared the main baseline
4 Anthropometric and hormonal factors and upper gastrointestinal cancer
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characteristics in the included participants (n = 476,160) to
those participants with no dietary or lifestyle information
(n = 6,259).
All analyses were conducted using SAS 9.4 software (SAS
Institute, Cary, NC) and p values <0.05 were considered statis-
tically signiﬁcant.
Results
During a mean follow-up of 14 years, 220 EA (171 men and
49 women), 195 ESCC (101 men and 94 women), 243 GC
(163 men and 80 women) and 373 GNC (184 men and
189 women) cases were diagnosed among the 476,160 partici-
pants (142,241 men and 333,919 women).
Anthropometric factors
In the overall cohort, 1.1% of participants were underweight,
37.8% were normal weight, 30.9% were overweight and 12.4%
were obese at baseline. Baseline characteristics by BMI catego-
ries are presented in Supporting Information Table S1. Obese
men and women were slightly older, had a higher WC and
HC, lower education level, less likely to be smokers, less
physically active and had a higher prevalence of diabetes than
normal weight subjects. In addition, obese men had a higher
intake of fruits and vegetables.
Several anthropometric variables were positively associated
with EA in both men and women (Tables 1 and 2), respec-
tively, including BMI (obese vs. normal weight, men: HR 1.94,
95% CI: 1.25–3.03; women: HR 2.66, 95% CI: 1.15–6.19), WC
(men: HR 2.39, 95% CI: 1.53–3.73 for >98 vs. <90 cm; women:
HR 2.81, 95% CI: 1.13–6.96 for WC >84 vs. <74 cm), WHR
(men: HR 3.21, 95% CI: 1.93–5.34 for >0.96 vs. <0.91; women:
HR 5.39, 95% CI: 1.74–16.72 for >0.82 vs. <0.76) and WHtR
(men: HR 2.36, 95% CI: 1.40–3.97 for >0.57 vs. <0.51; women:
HR 3.50, 95% CI: 1.24–9.93 for >0.52 vs. <0.45). In addition,
weight and HC were positively associated with EA in men but
not in women (Tables 1 and 2).
We observed inverse associations between some anthropo-
metric variables and ESCC, including weight and HC in both
men and women (Tables 1 and 2) and speciﬁcally BMI in men
(HR 0.52, 95% CI: 0.28–0.95 for obese vs. normal weight;
p-value for interaction by sex = 0.009; Table 1), and WC in
women (HR 0.55, 95% CI: 0.30–0.99 for WC >84 vs. <74 cm),
although the p-value for interaction by sex was not statistically
signiﬁcant (Table 2).
WHR was positively associated with GC in both men and
women, although the association was not statistically signiﬁ-
cant in men (HR 1.57, 95% CI: 0.97–2.53 for WHR >0.96 vs.
<0.91 and HR 2.50, 95% CI: 1.19–5.25 for WHR >0.82 vs.
<0.76, respectively; Tables 1 and 2). In addition, weight and
WC were positively associated with GC in women (Table 2).
For GNC, there was an inverse association between height
and GNC in men (HR 0.49, 95% CI: 0.30–0.81 for height
>178 vs. <171 cm) but not in women (HR 0.97, 95% CI:
0.63–1.51 for height >165 vs. <159 cm; Tables 1 and 2).
BMI and WHR were moderately correlated (r = 0.43), as
were WC and HC (r = 0.67). Upon adjustment for WHR, BMI
was no longer signiﬁcantly associated with EA in men or women
(HR 1.21, 95% CI: 0.75–1.97 and HR 1.93, 95% CI: 0.80–4.68
for obese vs. normal weight, respectively; Tables 3 and 4). Con-
versely, the positive association observed for WC and WHR in
relation to EA remained signiﬁcant in both men and women
after adjustment for HC and BMI, respectively (Tables 3 and 4).
Furthermore, the positive association observed between HC and
EA in men was attenuated after adjustment for WC (Table 3).
For ESCC, the inverse association observed with BMI and HC
in men remained signiﬁcant after adjustment for WHR and
WC, respectively (Table 3). In contrast, a positive association
was observed in men for ESCC with WC adjusted for HC
(HR 2.14, 95% CI: 1.06–4.32 for WC >98 vs. <90 cm) and WHR
adjusted for BMI (HR 2.24, 95% CI: 1.16–4.32 for WHR >0.96
vs. <0.91; Table 3). While in women, the inverse association
observed for ESCC with WC and HC was no longer signiﬁcant
after mutual adjustment (Table 4).
After adjustment for BMI, WHR remained positively asso-
ciated with GC in women (Table 4). A positive association
was found between WC and GC in men after adjustment for
HC (HR 1.99, 95% CI: 1.10–3.59 for >98 vs. <90 cm; Table 3).
While the positive association observed for GC with WC in
women was attenuated after adjustment for HC (HR 2.29,
95% CI: 0.92–5.72 for WC >84 vs. <74 cm; Table 4). For
GNC, results did not change when we mutually adjusted for
BMI and WHR or when WC and HC were mutually adjusted
in either men or women (Tables 3 and 4).
No statistically signiﬁcant interactions were observed
between BMI or smoking status and any of the outcomes.
Reproductive factors
Baseline characteristics of women according to OC and meno-
pausal hormonal use are presented in Supporting Information
Table S2. Women who reported using OC pills were younger,
had a slightly lower WC and HC, were more educated, more
likely to be smokers and more physically active, had a lower
intake of fruits and vegetables and lower prevalence of diabetes
compared to nonusers of OC. While women who reported using
hormones for menopause were slightly older and less educated
than nonusers.
We found no associations between reproductive factors and
ESCC or GC (Table 5). However, an inverse association was
observed between parity and EA (HR 0.38, 95% CI: 0.14–0.99
for >2 vs. 0 pregnancies). For GNC, compared to women who
had their ﬁrst pregnancy at an earlier age (<22 years), women
who had their pregnancy at a later age (>26 years) had a lower
risk of GNC (HR 0.54, 95% CI: 0.32–0.91). In addition, com-
pared to women who had not undergone ovariectomy, women
who had a bilateral ovariectomy had a higher risk of GNC
(HR 1.87, 95% CI: 1.04–3.36), although there were only 13 cases
in this group.
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Table 1. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in men (n = 142,241) according to anthropometric
factors in the EPIC study
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Men1 Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR3
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR2
(95% CI)
Height (cm)
<171 49 Reference 40 Reference 49 Reference 87 Reference
171–178 62 1.00 (0.68–1.47) 32 0.64 (0.39–1.05) 69 1.10 (0.75–1.63) 74 1.03 (0.74–1.44)
>178 59 1.30 (0.87–1.96) 29 0.74 (0.44–1.27) 45 0.98 (0.63–1.53) 22 0.49 (0.30–0.81)
Missing 1 – – – 1 –
ptrend 0.30 0.21 0.81 0.008
Weight (kg)
<75 42 Reference 47 Reference 51 Reference 64 Reference
75–84 53 1.15 (0.76–1.73) 26 0.49 (0.30–0.79) 59 1.03 (0.70–1.51) 64 0.91 (0.64–1.30)
>84 75 1.78 (1.21–2.63) 28 0.51 (0.31–0.82) 52 0.98 (0.65–1.45) 53 0.84 (0.58–1.23)
Missing 1 – – – 1 – 3
ptrend 0.006 0.003 0.96 0.68
BMI (kg/m2)4
Underweight5 – – 1 – 1 – 1 –
Normal weight 50 Reference 53 Reference 51 Reference 49 Reference
Overweight 83 1.15 (0.80–1.65) 31 0.38 (0.24–0.61) 90 1.22 (0.86–1.75) 99 1.13 (0.79–1.62)
Obese 37 1.94 (1.25–3.03) 16 0.52 (0.28–0.95) 20 0.94 (0.55–1.61) 32 1.03 (0.64–1.65)
Missing 1 – – 1 – 3 –
ptrend 0.02 0.0004 0.56 0.85
Hip circumference (cm)
<98 35 Reference 48 Reference 54 Reference 49 Reference
98–103 67 1.75 (1.16–2.64) 30 0.57 (0.36–0.91) 53 0.90 (0.61–1.33) 65 1.11 (0.76–1.62)
>103 52 1.59 (1.02–2.47) 17 0.29 (0.16–0.54) 45 0.90 (0.60–1.37) 51 0.82 (0.54–1.26)
Missing 17 – 6 – 11 – 19 –
ptrend 0.03 0.0002 0.84 0.31
Waist circumference (cm)
<90 30 Reference 29 Reference 32 Reference 39 Reference
90–98 50 1.46 (0.92–2.32) 36 0.89 (0.54–1.47) 66 1.54 (0.99–2.37) 73 1.32 (0.88–1.97)
>98 75 2.39 (1.53–3.73) 31 0.70 (0.41–1.21) 55 1.41 (0.89–2.22) 55 0.86 (0.55–1.34)
Missing 16 – 5 – 10 – 17 –
ptrend 0.0003 0.42 0.15 0.06
Waist-to-hip ratio
<0.91 21 Reference 18 Reference 25 Reference 32 Reference
0.91–0.96 52 1.72 (1.02–2.90) 36 1.17 (0.65–2.08) 63 1.39 (0.87–2.22) 81 1.42 (0.93–2.17)
>0.96 81 3.21 (1.93–5.34) 41 1.26 (0.70–2.29) 64 1.57 (0.97–2.53) 52 0.90 (0.57–1.43)
Missing 17 – 6 – 11 – 19 –
ptrend <0.0001 0.74 0.19 0.03
Waist-to-height ratio
<0.51 23 Reference 26 Reference 28 Reference 26 Reference
0.51–0.57 76 1.76 (1.09–2.86) 43 0.80 (0.48–1.31) 83 1.31 (0.84–2.03) 82 1.29 (0.82–2.04)
>0.57 56 2.36 (1.40–3.97) 27 0.69 (0.37–1.26) 42 1.13 (0.68–1.88) 59 1.02 (0.61–1.71)
Missing 16 – 5 – 10 – 17 –
ptrend 0.006 0.47 0.44 0.31
1Sex-specific tertiles were used in the analyses except for BMI.
2Stratified on age, center and adjusted for smoking and education level.
3Stratified on age, center and adjusted for smoking, education level and alcohol intake.
4Underweight (BMI <18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
5We excluded underweight group from the analysis due to few number of cases.
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Table 2. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in women (n = 333,919) according to
anthropometric factors in the EPIC study
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Women1 Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR3
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR2
(95% CI)
Height (cm)
<159 18 Reference 20 Reference 19 Reference 74 Reference
159–165 13 0.58 (0.27–1.25) 38 1.44 (0.82–2.55) 29 1.26 (0.69–2.32) 58 0.89 (0.61–1.28)
>165 16 1.01 (0.48–2.13) 31 1.49 (0.80–2.76) 23 1.29 (0.66–2.53) 41 0.97 (0.63–1.51)
Missing 2 – 5 – 9 – 16 –
ptrend 0.27 0.39 0.71 0.79
Weight (kg)
<60 9 Reference 38 Reference 12 Reference 48 Reference
60–69 15 1.29 (0.56–3.00) 29 0.63 (0.38–1.03) 22 1.63 (0.79–3.34) 49 0.76 (0.51–1.14)
>69 23 1.88 (0.85–4.16) 22 0.52 (0.30–0.90) 37 2.77 (1.40–5.48) 77 1.12 (0.77–1.64)
Missing 2 – 5 – 9 – 15 –
ptrend 0.25 0.04 0.001 0.10
BMI (kg/m2)4
Underweight5 1 – 6 – – – 2 –
Normal weight 13 Reference 45 Reference 29 Reference 68 Reference
Overweight 22 2.15 (1.06–4.38) 33 1.08 (0.68–1.72) 30 1.44 (0.85–2.43) 61 0.96 (0.67–1.38)
Obese 11 2.66 (1.15–6.19) 5 0.50 (0.20–1.28) 12 1.41 (0.70–2.83) 42 1.31 (0.86–2.00)
Missing 2 – 5 – 9 – 16 –
ptrend 0.09 0.003 0.56 0.49
Hip circumference (cm)
<96 14 Reference 37 Reference 13 Reference 43 Reference
96–104 14 0.78 (0.36–1.70) 32 0.80 (0.49–1.31) 29 1.83 (0.94–3.56) 53 0.82 (0.54–1.24)
>104 18 1.11 (0.53–2.34) 17 0.51 (0.28–0.95) 26 1.97 (0.98–3.95) 63 0.94 (0.62–1.44)
Missing 3 – 8 – 12 – 30 –
ptrend 0.64 0.10 0.13 0.59
Waist circumference (cm)
<74 7 Reference 29 Reference 10 Reference 35 Reference
74–84 16 1.62 (0.65–4.08) 35 0.71 (0.42–1.19) 25 1.59 (0.75–3.36) 50 0.79 (0.51–1.24)
>84 23 2.81 (1.13–6.96) 22 0.55 (0.30–0.99) 34 2.55 (1.22–5.33) 74 0.97 (0.62–1.53)
Missing 3 – 8 – 11 – 30 –
ptrend 0.06 0.13 0.03 0.47
Waist-to-hip ratio
<0.76 4 Reference 23 Reference 10 Reference 23 Reference
0.76–0.82 22 3.83 (1.28–11.44) 37 0.90 (0.52–1.56) 25 1.50 (0.71–3.17) 69 1.54 (0.94–2.51)
>0.82 20 5.39 (1.74–16.72) 26 0.73 (0.39–1.34) 33 2.50 (1.19–5.25) 67 1.49 (0.89–2.48)
Missing 3 – 8 – 12 – 30 –
ptrend 0.01 0.57 0.03 0.21
Waist-to-height ratio
<0.45 5 Reference 23 Reference 9 Reference 23 Reference
0.45–0.52 18 1.87 (0.67–5.19) 41 0.76 (0.44–1.31) 31 1.53 (0.72–3.26) 55 0.91 (0.54–1.52)
>0.52 23 3.50 (1.24–9.93) 20 0.53 (0.27–1.03) 29 2.05 (0.93–4.51) 80 1.27 (0.75–2.16)
Missing 3 – 10 – 11 – 31 –
ptrend 0.03 0.17 0.19 0.20
1Sex-specific tertiles were used in the analyses except for BMI.
2Stratified on age, center and adjusted for smoking, and education level.
3Stratified on age, center and adjusted for smoking, education level, and alcohol intake.
4Underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
5We excluded underweight group from the analysis due to few number of cases.
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Exclusion of esophageal and gastric cancer cases diagnosed in
the ﬁrst 2 years of follow-up did not substantially change the
associations observed for anthropometric or reproductive factors
(data not shown). In addition, analyses restricted to measured
anthropometric factors yielded similar results to those when par-
ticipants with self-reported data were included (data not shown).
Finally, comparing the baseline characteristics of included partic-
ipants to those excluded from the analysis because they lacked
dietary or lifestyle information, revealed no substantial differ-
ences between the two groups, except participants excluded were
very slightly older than the included participants.
Discussion
In this large prospective study, abdominal obesity was positively
associated with EA and GC, while the ﬁndings for ESCC were less
clear. No associations were observed for GNC either with general
or abdominal obesity. With regards to reproductive factors in
women, there were inverse associations between parity and EA
and between age at ﬁrst pregnancy and GNC; whereas a positive
association was observed for bilateral ovariectomy and GNC.
A number of meta-analyses have shown that BMI was pos-
itively associated with EA and GC.11,12,32 Our study found a
positive association between BMI and EA but these associa-
tions attenuated after adjustment for WHR, and no signiﬁcant
association was observed between BMI and GC independently
of WHR. The NIH-AARP Diet and Health Study, a prospec-
tive cohort study of equivalent size to EPIC, showed a nonsig-
niﬁcant positive association between BMI and EA (HR 1.77,
95% CI: 0.90–3.49; for BMI ≥35 vs. 18.5 to <25) and a signiﬁ-
cant positive association between BMI and GC (HR 3.28, 95%
CI: 1.76–6.11 for BMI ≥35 vs. 18.5 to <25) after adjustment
for WHR.15 A nested case–control study also reported no
Table 3. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in men (n = 142,241) according to anthropometric
factors (mutually adjusted) in the EPIC study
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Men1 Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR3
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR2
(95% CI)
BMI (kg/m2)4 adjusted for waist-to-hip ratio
Underweight5 – – 1 – 1 – 1 –
Normal weight 50 Reference 53 Reference 51 Reference 49 Reference
Overweight 83 0.88 (0.60–1.28) 31 0.31 (0.19–0.50) 90 1.06 (0.73–1.55) 99 1.15 (0.79–1.67)
Obese 37 1.21 (0.75–1.97) 16 0.37 (0.19–0.71) 20 0.75 (0.42–1.34) 32 1.15 (0.69–1.92)
Missing 1 – 1 3
ptrend 0.47 <0.0001 0.51 0.83
Waist circumference (cm) adjusted for hip circumference
<90 30 Reference 29 Reference 32 Reference 39 Reference
90–98 50 1.41 (0.85–2.32) 36 1.38 (0.80–2.36) 66 1.87 (1.16–3.00) 73 1.31 (0.84–2.05)
>98 75 2.67 (1.52–4.72) 31 2.14 (1.06–4.32) 55 1.99 (1.10–3.59) 55 0.90 (0.51–1.59)
Missing 16 – 5 – 10 – 17 –
ptrend 0.001 0.11 0.03 0.14
Hip circumference (cm) adjusted for waist circumference
<98 35 Reference 48 Reference 54 Reference 49 Reference
98–103 67 1.28 (0.80–2.04) 30 0.42 (0.25–0.73) 53 0.68 (0.44–1.05) 65 1.06 (0.69–1.63)
>103 52 0.82 (0.47–1.45) 17 0.17 (0.08–0.37) 45 0.62 (0.36–1.06) 51 0.92 (0.53–1.58)
Missing 17 – 6 – 11 – 19 –
ptrend 0.08 <0.0001 0.15 0.79
Waist-to-hip ratio adjusted for BMI
<0.91 21 Reference 18 Reference 25 Reference 32 Reference
0.91–0.96 52 1.82 (1.06–3.11) 36 1.57 (0.87–2.84) 63 1.37 (0.84–2.23) 81 1.33 (0.86–2.06)
>0.96 81 3.47 (1.99–6.06) 41 2.24 (1.16–4.32) 64 1.60 (0.94–2.71) 52 0.81 (0.49–1.35)
Missing 17 – 6 – 11 – 19 –
ptrend <0.0001 0.05 0.16 0.02
1Sex-specific tertiles were used in the analyses except for BMI.
2Stratified on age, center and adjusted for smoking and education level.
3Stratified on age, center and adjusted for smoking, education level and alcohol intake.
4Underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
5We excluded underweight group from the analysis due to few number of cases.
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association between BMI and EA after adjustment for abdom-
inal diameter.33
In our study, WHR and WC were positively associated with
EA independently of BMI and HC. WHR was also positively
associated with GC in women only independently of BMI, and
WC was positively associated with GC in men after adjustment
for HC. The NIH-AARP Diet and Health Study showed a posi-
tive association between WHR and EA (HR 1.17, 95% CI:
0.99–2.18; for Quartile 4 vs. Quartile 1), but no association
between WHR and GC (HR 1.08, 95% CI: 0.71–1.63; for Quar-
tile 4 vs. Quartile 1) when adjusted for BMI.15 This cohort study
also showed a positive association between WC and risk of EA
and GC, after adjustment for HC.15 In addition, two other
cohort studies showed a positive association between WC and
EA but these ﬁndings were not adjusted for HC.33,34 A recent
meta-analysis of six prospective studies reported positive associ-
ations for GC with WC but not with WHR.35
Taken together, our ﬁndings show that WC and WHR
rather than BMI appears to be more closely associated with
EA and GC. These associations could potentially be explained
by mechanical effects of obesity, especially abdominal obesity-
promoting GERD, which is associated with an increased risk
of EA and GC.16,33
In our study, the ﬁndings for ESCC were less clear; for exam-
ple, in men, HC and BMI were inversely associated with ESCC,
while WC and WHR were positively associated. A number of
prospective cohort studies have reported an inverse association
between BMI and ESCC.2,7,14 Few epidemiological studies have
examined the association between abdominal obesity and ESCC
and those that have reported no associations.33,34 The underlying
mechanisms for the observed associations between adiposity and
ESCC are not well-known and need to be further investigated but
our study sheds further light on the contrasting observations for
anthropometric measures and ESCC.
Table 4. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite in women (n = 333,919) according to
anthropometric factors (mutually adjusted) in the EPIC study
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Women1 Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR3
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR2
(95% CI)
BMI (kg/m2)4 adjusted for waist-to-hip ratio
Underweight5 1 – 6 – – – 2 –
Normal weight 13 Reference 45 Reference 29 Reference 68 Reference
Overweight 22 1.76 (0.85–3.64) 33 1.09 (0.67–1.76) 30 1.20 (0.70–2.07) 61 0.92 (0.63–1.33)
Obese 11 1.93 (0.80–4.68) 5 0.51 (0.20–1.34) 12 1.05 (0.50–2.19) 42 1.23 (0.79–1.93)
Missing 2 – 5 – 9 – 16 –
ptrend 0.29 0.004 0.92 0.53
Waist circumference (cm) adjusted for hip circumference
<74 7 Reference 29 Reference 10 Reference 35 Reference
74–84 16 2.44 (0.91–6.58) 35 0.78 (0.44–1.38) 25 1.39 (0.62–3.14) 50 0.86 (0.52–1.41)
>84 23 5.67 (1.76–18.26) 22 0.74 (0.34–1.59) 34 2.29 (0.92–5.72) 74 1.06 (0.59–1.93)
Missing 3 – 8 – 11 – 30 –
ptrend 0.01 0.65 0.15 0.57
Hip circumference (cm) adjusted for waist circumference
<96 14 Reference 37 Reference 13 Reference 43 Reference
96–104 14 0.44 (0.19–1.05) 32 0.89 (0.52–1.55) 29 1.43 (0.68–3.02) 53 0.83 (0.51–1.33)
>104 18 0.39 (0.15–1.05) 17 0.61 (0.28–1.34) 26 1.20 (0.50–2.90) 63 0.88 (0.50–1.55)
Missing 3 – 8 – 12 – 30 –
ptrend 0.12 0.45 0.58 0.73
Waist-to-hip ratio adjusted for BMI
<0.76 4 Reference 23 Reference 10 Reference 23 Reference
0.76–0.82 22 3.58 (1.19–10.81) 37 0.98 (0.56–1.72) 25 1.43 (0.68–3.05) 69 1.56 (0.95–2.56)
>0.82 20 4.40 (1.35–14.33) 26 0.91 (0.47–1.74) 33 2.34 (1.07–5.12) 67 1.48 (0.86–2.55)
Missing 3 – 8 – 12 – 30 –
ptrend 0.04 0.94 0.07 0.23
1Sex-specific tertiles were used in the analyses except for BMI.
2Stratified on age, center and adjusted for smoking, and education level.
3Stratified on age, center and adjusted for smoking, education level, and alcohol intake.
4Underweight (BMI <18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥30).
5We excluded underweight group from the analysis due to few number of cases.
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Table 5. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite according to reproductive factors in women
(n = 333,919) in the EPIC study
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Cases
Adjusted HR1
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR1
(95% CI) Cases
Adjusted HR1
(95% CI)
Age at menarche, years
<12 3 0.38 (0.11–1.24) 13 1.12 (0.60–2.07) 8 0.77 (0.36–1.63) 27 1.18 (0.77–1.83)
12–14 38 Reference 60 Reference 52 Reference 117 Reference
>14 6 0.50 (0.21–1.21) 17 0.83 (0.48–1.44) 16 0.93 (0.53–1.64) 33 0.91 (0.61–1.35)
Missing 2 – 4 – 4 – 12 –
ptrend 0.10 0.71 0.78 0.63
Duration of menstrual cycle, years
<30 5 Reference 14 Reference 15 Reference 36 Reference
30–35 15 1.74 (0.57–5.35) 29 1.02 (0.52–2.01) 16 0.56 (0.26–1.22) 63 1.23 (0.76–1.99)
>35 16 1.46 (0.48–4.48) 34 1.14 (0.58–2.24) 37 1.11 (0.57–2.18) 63 1.04 (0.64–1.69)
Missing 13 – 17 – 12 – 27 –
ptrend 0.62 0.90 0.01 0.56
Ever been pregnant
No 6 Reference 11 Reference 5 Reference 18 Reference
Yes 41 0.72 (0.30–1.72) 80 0.99 (0.51–1.91) 74 1.56 (0.63–3.89) 158 0.95 (0.58–1.56)
Missing 2 – 3 – 1 – 13 –
Age at first pregnancy, years
<22 6 Reference 22 Reference 22 Reference 38 Reference
22–26 13 1.18 (0.43–3.23) 25 0.54 (0.29–1.01) 25 0.70 (0.38–1.27) 55 0.65 (0.42–1.00)
>26 14 1.99 (0.70–5.59) 15 0.53 (0.26–1.10) 15 0.81 (0.40–1.64) 31 0.54 (0.32–0.91)
Missing 16 – 32 – 18 – 65 –
ptrend 0.30 0.11 0.50 0.05
Parity (number of full-term pregnancies)
0 8 Reference 13 Reference 7 Reference 19 Reference
1–2 27 0.69 (0.31–1.54) 57 1.16 (0.62–2.18) 47 1.34 (0.60–2.99) 94 1.03 (0.62–1.70)
>2 10 0.38 (0.14–0.99) 18 0.66 (0.32–1.38) 23 1.10 (0.47–2.59) 58 1.05 (0.62–1.80)
Missing 4 – 6 – 3 – 18 –
ptrend 0.12 0.13 0.64 0.98
Number of live-born children
1 9 Reference 17 Reference 10 Reference 15 Reference
2–3 23 0.54 (0.25–1.18) 44 0.74 (0.41–1.35) 38 0.79 (0.39–1.61) 64 0.88 (0.50–1.57)
>3 4 0.34 (0.09–1.31) 6 0.52 (0.19–1.40) 10 1.15 (0.46–2.88) 16 0.91 (0.43–1.93)
Missing 13 – 27 – 22 – 94 –
ptrend 0.18 0.40 0.54 0.91
Ever breastfeed
No 14 Reference 20 Reference 19 Reference 43 Reference
Yes 29 0.63 (0.33–1.22) 61 1.07 (0.64–1.81) 54 0.86 (0.51–1.47) 120 0.83 (0.58–1.19)
Missing 6 – 13 – 7 – 26 –
Duration of breastfeeding (months)
<4 11 Reference 20 Reference 20 Reference 31 Reference
4–10 8 0.72 (0.28–1.86) 20 1.01 (0.52–1.95) 18 0.86 (0.44–1.67) 42 1.17 (0.72–1.89)
>10 10 0.78 (0.31–1.94) 20 1.24 (0.63–2.43) 16 0.90 (0.45–1.83) 47 1.25 (0.76–2.06)
Missing 20 – 34 – 26 – 69 –
ptrend 0.77 0.77 0.90 0.67
(Continues)
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Our study found no association for GNC with BMI, WC or
WHR, which is in line with previous meta-analyses.32,35 How-
ever, we observed an inverse association between height and
GNC in men only. Previous cohort studies that examined the
association between height and GNC showed a nonsigniﬁcant
inverse association.7,15,36 The observed association could poten-
tially be explained by the positive association between GNC
and Helicobacter pylori infection, which may cause poor growth
during childhood and has been associated with lower socioeco-
nomic status,37,38 which is in turn related to poor nutrition and
leads to shorter adult height.39
With respect to reproductive factors, we found no associations
between reproductive factors and ESCC or GC. However, an
inverse association was observed between parity and EA. A meta-
analysis by Wang et al.21 reported no association for EA with
reproductive factors; however, this analysis did show an inverse
association between breastfeeding and EA.21 A recent meta-
analysis reported an inverse association between breastfeeding,
parity and esophageal cancer.22
Few epidemiological studies have studied the association
between age at ﬁrst pregnancy and upper gastrointestinal can-
cers. The Women’s Health Initiative Study reported no
Table 5. Adjusted hazard ratios for esophageal and gastric cancer by subtype and subsite according to reproductive factors in women
(n = 333,919) in the EPIC study (Continued)
Esophageal cancer Gastric cancer
Adenocarcinoma Squamous cell carcinoma Cardia Noncardia
Cases
Adjusted HR1
(95% CI) Cases
Adjusted HR2
(95% CI) Cases
Adjusted HR1
(95% CI) Cases
Adjusted HR1
(95% CI)
Menopause status
Pre/perimenopausal 9 Reference 18 Reference 23 Reference 49 Reference
Postmenopausal 36 2.12 (0.76–5.89) 73 2.14 (0.95–4.79) 51 0.83 (0.39–1.76) 127 1.31 (0.72–2.38)
Surgical menopause 4 3.66 (0.96–13.96) 3 1.45 (0.35–5.95) 6 1.70 (0.60–4.85) 13 2.26 (0.99–4.95)
Age at menopause, years
<48 10 Reference 19 Reference 13 Reference 35 Reference
48–51 14 1.34 (0.58–3.13) 26 1.37 (0.74–2.55) 19 1.27 (0.62–2.60) 55 1.34 (0.87–2.07)
>51 4 0.51 (0.16–1.70) 18 1.20 (0.60–2.38) 15 1.34 (0.62–2.93) 34 0.98 (0.60–1.59)
Missing 21 – 31 – 33 – 65 –
ptrend 0.24 0.61 0.73 0.26
Ever use of hormones for menopause
No 30 Reference 58 Reference 49 Reference 119 Reference
Yes 14 0.96 (0.49–1.89) 28 0.93 (0.57–1.53) 27 1.01 (0.61–1.67) 47 1.03 (0.71–1.50)
Missing 5 – 8 – 4 – 23 –
Duration of hormone use for menopause (years)
<2 7 Reference 12 Reference 11 Reference 15 Reference
≥2 7 0.85 (0.28–2.62) 10 0.76 (0.30–1.94) 13 0.88 (0.37–2.06) 24 1.40 (0.69–2.84)
Missing 35 – 72 – 56 – 150 –
Ever use of OC pill use
No 25 Reference 45 Reference 36 Reference 102 Reference
Yes 21 0.81 (0.41–1.58) 44 1.02 (0.61–1.69) 41 1.07 (0.64–1.78) 74 0.93 (0.66–1.33)
Missing 3 – 5 – 3 – 13 –
Duration of OC pill use (years)
<5 8 Reference 16 Reference 13 Reference 28 Reference
≥5 12 0.92 (0.37–2.32) 22 1.05 (0.52–2.11) 26 1.63 (0.81–3.30) 39 1.03 (0.61–1.73)
Missing 29 – 56 – 41 – 122 –
Ovariectomy
No 35 Reference 66 Reference 58 Reference 119 Reference
Unilateral – – 3 0.51 (0.13–2.11) 3 0.80 (0.25–2.55) 12 1.64 (0.88–3.06)
Bilateral 4 1.94 (0.68–5.54) 3 0.73 (0.22–2.42) 6 1.98 (0.84–4.65) 13 1.87 (1.04–3.36)
Missing 10 – 22 – 13 – 45 –
1Stratified on age, center and adjusted for smoking, BMI and education level.
2Stratified on age, center and adjusted for smoking, BMI, education level and alcohol intake.
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association between age at ﬁrst pregnancy and ESCC but this
was restricted to postmenopausal women.26 Furthermore, a
population-based case–control study showed no association
between age at ﬁrst pregnancy and distal gastric cancer (odds
ratio: 0.83, 95% CI: 0.44–1.57, for ≥25 years vs. nulliparous).40
No other study has reported an inverse association between
age at ﬁrst pregnancy and GNC.
Our updated analysis with longer follow-up conﬁrms the
previously reported positive association between bilateral
ovariectomy and GNC.28 While the NIH-AARP Diet and
Health Study reported a nonsigniﬁcant increased risk for EA
and GC combined (n = 65 cases) in women who had under-
gone ovariectomy,27 the Million Women’s Study Cohort
reported no association with GC or GNC.25 As estrogen has
been suggested as a protective factor for EA and gastric
cancer,41,42 ovariectomy and consequently decreased estrogen
levels could explain the increased risk of GNC in these indi-
viduals. Interestingly, studies in animal models have shown
that ovariectomized female mice had an increased risk of gas-
tric cancer.41
Our results suggest hormonal factors may play a role in
the etiology of upper gastrointestinal cancers but the underly-
ing biology is not deﬁned. For gastric cancer, estrogens may
protect against the development of this malignancy by acting
on estrogen receptors (ERα and ERβ), which have been identi-
ﬁed in gastric cancer cells.43 Estrogen inhibits cell growth and
increases apoptosis in gastric cancer cells44,45 and stimulates
the expression of trefoil factor proteins, which play a role in
mucosal protection and repair and their trefoil factor genes
may act as tumor suppressors.41
Estrogen regulates body adiposity and fat distribution
through ERs in the brain, and by interacting with leptin path-
ways.46 Body fat distribution varies by sex as men tend to
accrue more visceral fat, while women accrue more fat in the
subcutaneous depot.47 Estrogen promotes the accumulation of
subcutaneous fat48 and the decrease in estrogen levels in men-
opausal women is associated with an increase in visceral fat.49
The accumulation of visceral fat is associated with an
increased risk of esophageal and gastric cancer.35 Hence,
estrogen regulation of leptin levels in women may play a pro-
tective role directing accumulation of subcutaneous fat over
visceral fat and consequently may explain the sex differences
in the incidence of esophageal and gastric cancer.
However, any potential protective mechanisms associated
with estrogen are in conﬂict with the fact that obesity, which
has been linked with an increased risk of some upper gastro-
intestinal cancers, is associated with higher estrogen levels.
Nevertheless, the associations observed in our study were site-
speciﬁc, in that abdominal obesity was positively associated
with EA and GC (and not GNC) and bilateral ovariectomy
were only positively associated with GNC. Furthermore, in
addition to the effect on sex hormones, there are other biolog-
ical effects of obesity, including insulin resistance, where levels
of insulin and bioavailability of IGF are increased, which
promotes cell division and inhibits apoptosis.17 Obesity also
increases concentrations of adipokines (e.g., leptin) and
proinﬂammatory cytokines (e.g., tumor necrosis factor-α),
which may contribute to cancer development.17,18
Strengths of our study include its prospective study design,
large sample size and availability of standardized information
on reproductive factors, and potential confounders. In addi-
tion, anthropometric factors were mostly measured by trained
professionals. Due to the prospective nature of the study, the
likelihood of recall and selection bias is minimal. The large
sample size allowed the analyses of esophageal and gastric
cancer by subtype and subsite, and allowed analyses by gen-
der; however, despite the size of the cohort and the long-term
follow-up, the number of cases in some analyses was quite
small. Our study has some limitations. We used a single
assessment of anthropometric and reproductive factors col-
lected at baseline as data during follow-up was not available; if
anthropometric and reproductive factors changed during
follow-up, this could lead to some misclassiﬁcation and possi-
bly bias the results toward null. Although we adjusted for sev-
eral potential confounders, we lacked information on GERD
and Helicobacter pylori infection, which have been associated
with EA and GC, respectively; therefore, residual confounding
cannot be excluded. We also lacked data on the reason for
ovariectomy in the women who underwent this procedure. In
addition, EPIC cohort participants are of European descent,
which limits the generalizability of our ﬁndings to other eth-
nicities. Finally, as we analyzed anthropometric and reproduc-
tive factors in relation to both esophageal and gastric cancer
by subtype and subsite, some of our associations may have
arisen by chance as a result of multiple comparisons.
In conclusion, the results of our study suggest that abdomi-
nal obesity may inﬂuence risk for EA and GC. Furthermore,
some reproductive factors in women may inﬂuence risk for
EA and GNC, speciﬁcally. Together, these ﬁndings may sup-
port a role for hormonal pathways in upper gastrointestinal
cancer development; however, in order to fully investigate
these pathways, future studies should investigate endogenous
hormone measurements in relation to these cancers. Consid-
ering these results, maintaining a healthy weight should be
suggested as an evidence-based lifestyle recommendation for
EA and GC prevention.
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